Biosciences

Public-Private Collaboration Aims to Find a New Treatment for Pancreatic Cancer

Public-Private Collaboration Aims to Find a New Treatment for Pancreatic Cancer

At the HudsonAlpha Institute for Biotechnology, casual gatherings can lead to incredible research opportunities. A fortuitous encounter…

0 READ MORE

Considering Data Demand

Nonstop data demands accelerating growth of both large and small data centers
By David Hodes

As new advancements are made in the rapidly expanding cloud computing industry, companies are seeking to establish data centers in areas that are able to support and promote the enormous amount of computing power that…

27 May 11:41 AM 0 Read More...

Bringing Work to Life

Life Sciences and Biotech Gain Momentum
By Mark Kleszczewski

While not immune to lingering fallout from the 2008-09 economic crisis, the bioscience industry has weathered difficult times better than most industries and is on course to regain its previous high employment levels, according to the Biotechnology Innovation Association (BIO…

23 Mar 1:12 PM 0 Read More...

Breathing Life Back Into Bioscience

Caption:  3737 Market Street is the newest building on the University City Science Center’s campus, located in Philadelphia. Spark Therapeutics is one of the building’s residents, taking up an entire floor. Photo: CJ Dawson/Courtesy of the University City Science Center

By Mark Kleszczewski

Innovations blur the edges…

05 Apr 8:20 PM 0 Read More...

Bioscience’s Bright Spots

By Mark Kleszczewski

Collaboration within clusters trumps competition.

Despite high failure rates, difficulties in obtaining early-stage funding and rapidly-changing market dynamics, the U.S. bioscience and biopharma industries not only weathered the recession, but actually added jobs while other knowledge-based industries lost traction.
While well-established industry…

13 Jan 2:21 PM 1 Read More...

What’s in Store for Biopharma?

By Rachel Duran

For the biopharma industry, the so-called valley of death is where discoveries get stuck, unable to cross the valley and eventually become part of the biopharma pipeline. With a stagnant venture capital climate, the industry has become severely strained and pharmas are going out of business…

21 Apr 1:49 PM 0 Read More...